JP2023540732A5 - - Google Patents

Info

Publication number
JP2023540732A5
JP2023540732A5 JP2023514907A JP2023514907A JP2023540732A5 JP 2023540732 A5 JP2023540732 A5 JP 2023540732A5 JP 2023514907 A JP2023514907 A JP 2023514907A JP 2023514907 A JP2023514907 A JP 2023514907A JP 2023540732 A5 JP2023540732 A5 JP 2023540732A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
cdr2
cdr3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023514907A
Other languages
English (en)
Japanese (ja)
Other versions
JP7848189B2 (ja
JP2023540732A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/072595 external-priority patent/WO2022048883A1/en
Publication of JP2023540732A publication Critical patent/JP2023540732A/ja
Publication of JP2023540732A5 publication Critical patent/JP2023540732A5/ja
Application granted granted Critical
Publication of JP7848189B2 publication Critical patent/JP7848189B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023514907A 2020-09-04 2021-08-13 抗ｃｅａｃａｍ５抗体及びコンジュゲート並びにそれらの使用 Active JP7848189B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP20194711 2020-09-04
EP20194711.6 2020-09-04
EP20195559.8 2020-09-10
EP20195559 2020-09-10
PCT/EP2021/072595 WO2022048883A1 (en) 2020-09-04 2021-08-13 Anti-ceacam5 antibodies and conjugates and uses thereof

Publications (3)

Publication Number Publication Date
JP2023540732A JP2023540732A (ja) 2023-09-26
JP2023540732A5 true JP2023540732A5 (https=) 2024-08-21
JP7848189B2 JP7848189B2 (ja) 2026-04-20

Family

ID=77543503

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023514907A Active JP7848189B2 (ja) 2020-09-04 2021-08-13 抗ｃｅａｃａｍ５抗体及びコンジュゲート並びにそれらの使用

Country Status (15)

Country Link
US (1) US20250122282A2 (https=)
EP (2) EP4725500A2 (https=)
JP (1) JP7848189B2 (https=)
KR (1) KR20230062600A (https=)
CN (1) CN116113439A (https=)
AU (1) AU2021335257A1 (https=)
BR (1) BR112023001733A2 (https=)
CA (1) CA3190586A1 (https=)
CL (2) CL2023000630A1 (https=)
CO (1) CO2023004252A2 (https=)
IL (1) IL301004A (https=)
MX (1) MX2023002330A (https=)
PH (1) PH12023550266A1 (https=)
TW (1) TW202212362A (https=)
WO (1) WO2022048883A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI851577B (zh) 2018-06-07 2024-08-11 美商思進公司 喜樹鹼結合物
CN116390771A (zh) 2020-07-13 2023-07-04 瑞泽恩制药公司 与蛋白中的谷氨酰胺残基缀合的喜树碱类似物及其用途
JP2023541637A (ja) * 2020-09-15 2023-10-03 シンアフィックス ビー．ブイ． 抗体－エクサテカンコンジュゲート
CA3241734A1 (en) * 2022-01-12 2023-07-20 Amy Han Camptothecin analogs conjugated to a glutamine residue in a protein, and their use
WO2023172968A1 (en) * 2022-03-09 2023-09-14 Merck Patent Gmbh Anti-gd2 antibodies, immunoconjugates and therapeutic uses thereof
WO2024091437A1 (en) * 2022-10-25 2024-05-02 Merck Sharp & Dohme Llc Exatecan-derived adc linker-payloads, pharmaceutical compositions, and uses thereof
EP4619045A1 (en) * 2022-11-17 2025-09-24 Sanofi Ceacam5 antibody-drug conjugates and methods of use thereof
TW202434306A (zh) * 2022-11-24 2024-09-01 瑞士商百濟神州瑞士有限責任公司 抗ｃｅａ抗體藥物軛合物及使用方法
EP4410313A1 (en) 2023-01-31 2024-08-07 Synaffix B.V. Homogeneous antibody-conjugates with high payload loading
KR20250169306A (ko) 2023-04-18 2025-12-02 아스트라제네카 아베 절단가능한 링커를 포함하는 접합체
CN121219019A (zh) 2023-05-05 2025-12-26 百欧恩泰欧洲股份公司 用于增强靶向癌症相关抗原的采用新型连接子-有效载荷系统的抗体药物偶联物
WO2024250925A1 (en) * 2023-06-05 2024-12-12 Nona Biosciences (Suzhou) Co., Ltd. Anti-ceacam5 antibodies
WO2025100827A1 (ko) * 2023-11-09 2025-05-15 주식회사 다안바이오테라퓨틱스 항 ceacam5 항체 및 이의 용도
US20250186604A1 (en) * 2023-12-06 2025-06-12 Adc Therapeutics Sa Anti-psma antibody conjugates
WO2025130991A1 (zh) * 2023-12-22 2025-06-26 上海亲合力生物医药科技股份有限公司 肿瘤微环境激活的药物偶联物及抗体药物偶联物
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
US12521446B2 (en) 2024-02-27 2026-01-13 Bristol-Myers Squibb Company Anti-CEACAM5 antibody drug conjugates
TW202602918A (zh) 2024-04-12 2026-01-16 大陸商四川科倫博泰生物醫藥股份有限公司 Ceacam5結合蛋白及其用途
WO2025242091A1 (zh) * 2024-05-21 2025-11-27 康诺亚生物医药科技（成都）有限公司 针对ceacam5的抗体及其用途
WO2025242099A1 (zh) * 2024-05-21 2025-11-27 康诺亚生物医药科技（成都）有限公司 针对cdh17的抗体偶联药物及其用途
WO2025242098A1 (zh) * 2024-05-21 2025-11-27 康诺亚生物医药科技（成都）有限公司 针对ceacam5的抗体偶联药物及其用途
WO2025242845A1 (en) 2024-05-22 2025-11-27 Merck Patent Gmbh Colorectal cancer treatment
WO2026012312A1 (en) 2024-07-09 2026-01-15 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Anti-ceacam5 antibody-drug conjugate and method for preparation and use thereof

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US244A (en) 1837-06-30 Edward flint
US5204A (en) 1847-07-24 james cantelo
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
DE3689123T2 (de) 1985-11-01 1994-03-03 Xoma Corp Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
WO1987005330A1 (en) 1986-03-07 1987-09-11 Michel Louis Eugene Bergh Method for enhancing glycoprotein stability
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5278056A (en) 1988-02-05 1994-01-11 The Trustees Of Columbia University In The City Of New York Retroviral packaging cell lines and process of using same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
DK0752248T3 (da) 1992-11-13 2000-11-13 Idec Pharma Corp Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig
DE69434860T2 (de) 1993-02-22 2007-03-15 The Rockefeller University Herstellung von helfer-freien retroviren mit hohem titer mittels transienter transfektion
FR2712812B1 (fr) 1993-11-23 1996-02-09 Centre Nat Rech Scient Composition pour la production de produits thérapeutiques in vivo.
DE69535243T2 (de) 1994-07-13 2007-05-10 Chugai Seiyaku K.K. Gegen menschliches interleukin-8 gerichteter, rekonstituierter menschlicher antikörper
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
ES2233974T3 (es) 1995-09-11 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. Anticuerpo contra la cadena alfa del receptor de la interleucina 5 humana.
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
JP2001522241A (ja) 1997-04-10 2001-11-13 ロイヤル ネザーランズ アカデミー オブ アーツ アンド サイエンシズ 診断方法および試薬
GB0308731D0 (en) 2003-04-15 2003-05-21 Anticancer Therapeutic Inv Sa Method of radiotherapy
WO2004094613A2 (en) 2003-04-22 2004-11-04 Ibc Pharmaceuticals Polyvalent protein complex
MX2009000709A (es) 2006-07-18 2009-02-04 Sanofi Aventis Anticuerpo antagonista contra epha2 para el tratamiento de cancer.
MX338397B (es) 2007-08-29 2016-04-15 Sanofi Aventis Anticuerpos anti - cxcr5 humanizados, derivados de los mismos y su uso.
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
EP2478110B1 (en) * 2009-09-16 2016-01-06 Immunomedics, Inc. Class i anti-cea antibodies and uses thereof
DK3199552T3 (da) * 2012-11-20 2020-03-30 Sanofi Sa Anti-ceacam5-antistoffer og anvendelser heraf

Similar Documents

Publication Publication Date Title
JP2023540732A5 (https=)
JP4294596B2 (ja) 糸球体腎炎および他の炎症性疾患の治療のための組成物および方法
JP2022180379A5 (https=)
JP2025090743A5 (https=)
JP2022553324A5 (https=)
JP2016519932A5 (https=)
JP2022502371A5 (https=)
JP2020519643A5 (https=)
CY1118037T1 (el) Αντισωματα εναντι του αβητα και h χρηση τους
RU2010116152A (ru) Антитело против рецептора il-6
JP2016511279A5 (https=)
EA200700136A1 (ru) Анти-cd154-антитела
JP2007526880A5 (https=)
NZ596409A (en) Anti macrophage migration inhibitory factor antibodies
NO20063026L (no) Antistoffer
NZ596865A (en) Single-chain multivalent binding proteins with effector function
AR069290A1 (es) Anticuerpos monoclonales que se unen al hgm -csf (factor estimulante de la colonia de granulocitos-macrofagos) y las composiciones medicas que los comprenden
JP2020530285A5 (https=)
JP2017113019A5 (https=)
JP2020516603A5 (https=)
UA102061C2 (ru) Агонистическое антитело к notch3 и его применение для лечения notch3- ассоциированных заболеваний
JP2022513331A5 (https=)
MX2022009150A (es) Anticuerpos multiespecificos, composiciones que los comprenden, y vectores y usos de los mismos.
EP3300739A3 (en) Antibodies and related molecules that bind to 161p2f10b proteins
WO2023280297A9 (zh) Cd19抗体及其应用